Regulatory mechanisms and role of the PI3K-TSC-mTOR signaling network in tumors

PI3K-TSC-mTOR信号网络在肿瘤中的调控机制和作用

• 批准号: 8449705
• 负责人: BRENDAN D. MANNING
• 金额: $ 24.28万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-13 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8449705
• 关键词: Autistic Disorder; Biological; Cell Line; Cells; Clinical; Clinical Research; Collaborations; Complex; Data; Defect; Development; Disease; Feedback; Genes; Genetic; Glioblastoma; Grant; Growth; Human; Image; Link; Lipids; Luciferases; Malignant Neoplasms; Measures; Mediating; Modeling; Molecular; Multiple Hamartoma Syndrome; Mus; Mutation; Neoplasm Metastasis; Neurofibromatoses; Non-Insulin-Dependent Diabetes Mellitus; Normal Cell; Oncogenic; Outcome; Pathway interactions; Phospho-Specific Antibodies; Phosphorylation; Phosphorylation Site; Phosphotransferases; Play; Property; Protein Kinase; Publications; Reagent; Receptor Protein-Tyrosine Kinases; Regulation; Reporting; Research; Role; Sampling; Signal Pathway; Signal Transduction; Sirolimus; Syndrome; TSC1 gene; TSC2 gene; Therapeutic Intervention; Time; Tissues; Tuberous sclerosis protein complex; Tumor Suppressor Genes; Tumor Suppressor Proteins; Tumor-Derived; Xenograft procedure; attenuation; cancer type; genetic analysis; human disease; in vivo; insight; interest; liquid chromatography mass spectrometry; mTOR protein; neoplastic cell; novel; public health relevance; therapeutic target; tumor; tumor growth; tumorigenesis

DESCRIPTION (provided by applicant): The delineation of complex signaling pathways and networks is providing therapeutic targets and strategies for cancer and greatly enhancing our ability to predict and interpret clinical outcomes. The pathways involving the lipid kinase PI3K and the protein kinase mTOR are intimately linked in a cellular network, referred to here as the PI3K-TSC-mTOR network, that is comprised of numerous oncogenes and tumor suppressors. Dysregulation of this signaling network occurs in the majority of genetic tumor syndromes, such as tuberous sclerosis complex (TSC), neurofibromatosis, and Cowden disease, and all of the most common forms of cancer. Research under the original grant and continued in this renewal is revealing the molecular wiring of this signaling network in normal and tumor cells and providing novel insights into tumor development, progression, and therapeutic intervention. Progress: Research during the first 3.5 years of the original 4-year grant has yielded several new breakthroughs in our understanding of feedback regulation and other critical control points within the PI3K-TSC-mTOR network, and these have been reported and discussed in 14 publications during this time. Of particular significance for this renewal were discoveries regarding the two functionally distinct mTOR complexes (mTORC1 and 2), which provided some of the first insights into the regulatory mechanisms controlling mTORC2 activity. Current Direction: The aims of the original grant were geared toward understanding signaling mechanisms and their effects in cell and tumor models of the TSC disease. While our intense interest in TSC continues, in this renewal we will also expand on these findings to understand the role of this signaling network in human malignancies. Given the nearly universal corruption of the PI3K-TSC-mTOR network in glioblastoma, Aim 3 is dedicated to defining the mechanisms leading to its misregulation and their consequences in these aggressive tumors. In contrast to our detailed understanding of mTORC1, we know very little regarding the regulatory mechanisms and functions of mTORC2. Therefore, building on our recent discoveries with mTORC2 and the increasing evidence that it plays a key role in promoting tumorigenesis, the aims of this renewal are focused on the mechanisms of mTORC2 regulation in normal cells and misregulation in tumors. The specific aims use a variety of cell and mouse tumor models, as well as clinical samples, and involve several key collaborators. Specific Aims: 1) To determine the mechanisms and consequences of our recent surprising finding that the TSC tumor suppressors, while inhibiting mTORC1, activate mTORC2. 2) To determine the molecular mechanisms leading to mTORC2 activation downstream of receptor tyrosine kinases. 3) To determine the role of mTORC2 activation and downstream signaling in glioblastoma.

描述（由申请人提供）：复杂信号通路和网络的描述为癌症提供了治疗靶点和策略，并极大地增强了我们预测和解释临床结果的能力。涉及脂质激酶 PI3K 和蛋白激酶 mTOR 的通路在细胞网络中紧密相连，此处称为 PI3K-TSC-mTOR 网络，由许多癌基因和肿瘤抑制因子组成。该信号网络的失调发生在大多数遗传性肿瘤综合征中，例如结节性硬化症 (TSC)、神经纤维瘤病和考登病，以及所有最常见的癌症形式。最初资助下的研究以及本次更新中继续进行的研究揭示了正常细胞和肿瘤细胞中该信号网络的分子线路，并为肿瘤的发生、进展和治疗干预提供了新的见解。进展：最初 4 年资助的前 3.5 年的研究在我们对 PI3K-TSC-mTOR 网络内的反馈调节和其他关键控制点的理解方面取得了一些新的突破，这些突破已在 14 篇出版物中进行了报道和讨论这段时间。对于这一更新具有特别重要意义的是关于两种功能不同的 mTOR 复合物（mTORC1 和 2）的发现，这为控制 mTORC2 活性的调节机制提供了一些初步见解。当前方向：最初拨款的目的是为了了解信号传导机制及其对 TSC 疾病的细胞和肿瘤模型的影响。虽然我们对 TSC 的浓厚兴趣仍在继续，但在本次更新中，我们还将扩展这些发现，以了解该信号网络在人类恶性肿瘤中的作用。鉴于胶质母细胞瘤中 PI3K-TSC-mTOR 网络几乎普遍腐败，Aim 3 致力于确定导致其失调的机制及其在这些侵袭性肿瘤中的后果。与我们对 mTORC1 的详细了解相反，我们对 mTORC2 的调控机制和功能知之甚少。因此，基于我们最近对 mTORC2 的发现以及越来越多的证据表明它在促进肿瘤发生中发挥关键作用，本次更新的目标集中在正常细胞中 mTORC2 调节和肿瘤中错误调节的机制。具体目标使用各种细胞和小鼠肿瘤模型以及临床样本，并涉及几个关键合作者。具体目标： 1) 确定我们最近令人惊讶的发现的机制和后果，即 TSC 肿瘤抑制因子在抑制 mTORC1 的同时激活 mTORC2。 2) 确定导致受体酪氨酸激酶下游mTORC2激活的分子机制。 3) 确定 mTORC2 激活和下游信号在胶质母细胞瘤中的作用。